TAK 637

structure in first source

Also Known As:

(aR,9R)-7-(3,5-bis(trifluoromethyl)benzyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-(1,4)diazocino(2 1-g)(1,7)naphthyridine-6,13-dione; TAK-637; TAK637

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Naphthyridines: 2
      - TAK 637: 4

Experts

1.	Gibson, Matthew S: 1 article (03/2003)
2.	Greenwood-Van Meerveld, Beverley: 1 article (03/2003)
3.	Johnson, Anthony C: 1 article (03/2003)
4.	Sutkowski-Markmann, Debra: 1 article (03/2003)
5.	Venkova, Kalina: 1 article (03/2003)
6.	Ikeura, Yoshinori: 1 article (03/2002)
7.	Inatomi, Nobuhiro: 1 article (03/2002)
8.	Okano, Shiho: 1 article (03/2002)
9.	Furness, J B: 1 article (10/2001)
10.	Ikeura, Y: 1 article (08/2001)

Related Diseases

1.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 08/01/2001 - "These results suggest that NK1 receptors in the enteric plexus play an important role in stress-induced changes in colonic function, and that TAK-637 may be useful in the treatment of functional bowel diseases such as irritable bowel syndrome." 10/01/2001 - "Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. "
2.	Visceral Pain 03/01/2002 - "These results suggest that tachykinin NK1 receptors play an important role in mediating visceral pain and that TAK-637 inhibits the viscerosensory response to colorectal distention by antagonizing tachykinin NK1 receptors, mainly in the spinal cord. " 03/01/2002 - "In this study, we investigated the role of tachykinin NK1 receptors in the visceral pain response (abdominal muscle contraction) caused by colorectal distention in rabbits previously subjected to colonic irritation, using the selective tachykinin NK1 receptor antagonists TAK-637 [(aR,9R)-7-[3,5-Bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4] diazocino[2,1-g][1,7]naphthyridine-6,13-dione] and (+/-)-CP-99,994 (+/-)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine. "
3.	Urinary Incontinence 10/01/2001 - "Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. "
4.	Hypersensitivity (Allergy) 03/01/2003 - "In both models of colonic hypersensitivity, oral administration of TAK-637 (0.1-10 mg/kg) normalized visceromotor responses. " 03/01/2003 - "The intracerebroventricular (10 microg/kg) or intrathecal (10 microg/kg) administration of TAK-637 inhibited colonic hypersensitivity, suggesting an interaction with central NK(1) receptors. "

Related Drugs and Biologics

1.	Tachykinins
2.	3- (2- methoxybenzylamino)- 2- phenylpiperidine
3.	Neurokinin-1 Receptors (Neurokinin 1 Receptor)

Related Therapies and Procedures

1.	Oral Administration